-
Mashup Score: 0Lung Cancers Today | Docwire News - 7 month(s) ago
Lung Cancers Today provides the latest research and clinical guidance updates on small cell and non-small cell lung cancer, mesothelioma, lung adenocarcinoma, and more.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3What Patients With NSCLC Say About Treatment-Related Toxicities, Therapeutic Drug Monitoring | Docwire News - 7 month(s) ago
Research is illuminating patient perspectives on treatment-related toxicities and therapeutic drug monitoring with tyrosine kinase inhibitors in non-small cell lung cancer.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 A new study published in @TAMedOncol is lending critical insights into patient perspectives on treatment-related toxicities and therapeutic drug monitoring with TKIs for the treatment of NSCLC. ➡️ Learn more: https://t.co/z8ARfEHXti #NSCLC #lcsm https://t.co/R0ODTQfsNc
-
-
Mashup Score: 0Lung Cancers Today | Docwire News - 7 month(s) ago
Lung Cancers Today provides the latest research and clinical guidance updates on small cell and non-small cell lung cancer, mesothelioma, lung adenocarcinoma, and more.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 The @IASLC #HTTR24 conference kicks off this afternoon in Washington, D.C.! ➡️ Stay tuned for our coverage: https://t.co/i8Aw6kHDzY #NSCLC #lcsm https://t.co/lf2lYCtFkN
-
-
Mashup Score: 0Lung Cancers Today | Docwire News - 7 month(s) ago
Lung Cancers Today provides the latest research and clinical guidance updates on small cell and non-small cell lung cancer, mesothelioma, lung adenocarcinoma, and more.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 The @IASLC #HTTR24 conference kicks off this afternoon in Washington, D.C.! ➡️ Stay tuned for our coverage: https://t.co/i8Aw6kHDzY #NSCLC #lcsm https://t.co/lf2lYCtFkN
-
-
Mashup Score: 4Nivolumab, Ipilimumab With or Without Chemotherapy Shows Benefit in Metastatic NSCLC | Docwire News - 7 month(s) ago
Nivolumab and ipilimumab, with or without chemotherapy, showed a “long-term, durable clinical benefit” for metastatic NSCLC, according to CheckMate 227 and CheckMate 9LA studies.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📋 Nivolumab plus ipilimumab with or without chemotherapy shows a "long-term, durable clinical benefit" in patients with mNSCLC and PD-L1 <1%, according to an analysis of CheckMate 227 & CheckMate 9LA by @peters_solange & colleagues. ➡️ Read more: https://t.co/3G56EPRZad #lcsm https://t.co/pAiTdjHvHe
-
-
Mashup Score: 2Deep Learning Approach Characterizes Tumor Microenvironment in NSCLC | Docwire News - 7 month(s) ago
HistoTME, a novel deep learning approach, can characterize the tumor microenvironment molecular composition and predict responses to immune checkpoint inhibitors in NSCLC.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 A novel deep learning approach may be an effective way to characterize the TME & predict responses to ICIs in NSCLC, according to research presented at #SITC24 by a team from @theNCI. ➡️ Learn more: https://t.co/LqNptHvtKG #lcsm #LungCancer #NSCLC https://t.co/GFHInDwBXM
-
-
Mashup Score: 3Dr. McWilliams Discusses the PanCan Nodule Management Protocol for Lung Cancer Screening | Docwire News - 7 month(s) ago
The plenary presentation at the IASLC 2024 World Conference on Lung Cancer focused on prospective validation of the PanCan nodule risk calculator and comparisons with LungRADSv1.1.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 What's the best method to triage lung cancer screening participants at program entry? 🎙️ In this video interview, hear insights from Annette McWilliams, MBBS, FRACP, PhD, of @uwanews. ➡️ Watch: https://t.co/KqkDJc4uih #lcsm #lungcancer https://t.co/LAAzi1OyE3
-
-
Mashup Score: 4
The US Food and Drug Administration (FDA) has approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC).
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 REGUALTORY UPDATE: The US Food and Drug Administration has approved durvalumab for adults with LS-SCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ➡️ Learn more: https://t.co/xv5SVGZG9j #SCLC #LCSM https://t.co/dj7fwVAB2F
-
-
Mashup Score: 2Can Trilaciclib Help Prevent Hematological Adverse Events With Chemotherapy in Patients With SCLC? | Docwire News - 7 month(s) ago
Trilaciclib, a drug approved for patients with extensive-stage small cell lung cancer, has “consistently demonstrated efficacy” in reducing chemotherapy-induced myelosuppresion.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 Trilaciclib, a drug approved for patients with extensive-stage SCLC, “consistently demonstrated efficacy” in reducing chemotherapy-induced myelosuppression, according to research by a team from @BeaumontHealth. ➡️ Read more: https://t.co/Ssea2jSMv4 https://t.co/QUoUekmRAn
-
-
Mashup Score: 8Real-World French Prospective Study on Lung Cancer Highlights Progress in NSCLC Since 2000 | Docwire News - 7 month(s) ago
Among the 2020 cohort of patients with NSCLC, the three-year survival rate was around 35%, with a median overall survival of 17.4 months.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 How have NSCLC outcomes changed over the decades? 🗨️ Didier Debieuvre, MD, joined us to share insights from a real-world prospective French study on lung cancer that has been conducted every 10 years since 2000. ➡️ Watch: https://t.co/kXOhWLCT0s #lcsm #LCAM #NSCLC https://t.co/XfQ51Z0qvn
-
📰 The @IASLC #HTTR24 conference kicks off this afternoon in Washington, D.C.! ➡️ Stay tuned for our coverage: https://t.co/i8Aw6kHDzY #NSCLC #lcsm https://t.co/lf2lYCtFkN